BillionToOne, Inc. BLLN
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +34.96%
- 1 year
- +1.39%
- Market cap
- 5.21B
- Revenue (ttm)
- 397.41M
- Profit margin
- 8.35%
- EPS (ttm)
- 0.63
- Shares out
- 42.64M
- P/E ratio
- 175.32
- Forward P/E
- 74.38
- YTD return
- +34.96%
- 1-year return
- +1.39%
- Volume
- 360.19K
- Avg volume
- 651.10K
- Open
- 110.63
- Previous close
- 110.41
- Day's range
- 109.56 – 113.40
- 52-week range
- 61.96 – 150.44
- Analysts
- Strong Buy
- Price target
- 129.00 (+16.8%)
- Earnings date
- Nov 4, 2026
1m -0.65 (-0.59%)
Key statistics
- Enterprise value
- 4.81B
- PEG ratio
- 0.00
- Price / sales
- 13.11
- Price / book
- 9.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 64.40%
- Free cash flow
- 12.03M
- Total cash
- 548.63M
- Total debt
- 143.92M
- Return on equity
- 10.68%
- Short % of float
- 11.22%
- 50-day average
- 104.12
- 200-day average
- 96.52
Analyst view
Consensus: strong buy
- Target (low)
- 110.00
- Target (mean)
- 129.00
- Target (high)
- 145.00
- Strong buy2
- Buy5
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.30.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.146 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.1833 | 0.15 | -0.03 | -18.17% |
| May 6, 2026 | Mar 31, 2026 | 0.01 | 0.34 | +0.33 | +3,300.00% |
| Mar 4, 2026 | Dec 31, 2025 | 0.07 | 0.11 | +0.04 | +57.14% |
| Dec 9, 2025 | Sep 30, 2025 | 0.1395 | 0.10 | -0.04 | -28.32% |
| Oct 7, 2025 | Jun 30, 2025 | 0.1395 | -0.02 | -0.16 | -114.34% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Sep 2, 2026 | Canaccord Genuity | init | — | Buy |
| Aug 6, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 6, 2026 | BTIG | main | Buy | Buy |
| Jun 29, 2026 | Guggenheim | init | Buy | Buy |
| May 13, 2026 | Guggenheim | main | Buy | Buy |
About BillionToOne, Inc.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- billiontoone.com
News
BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share 
BillionToOne (BLLN) Reports Next Week: Wall Street Expects Earnings Growth 
BillionToOne to Participate in Two Upcoming Investor Conferences 
Billiontoone (NASDAQ:BLLN) CEO Sells $516,184.50 in Stock 
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026 
BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentials 
BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds 
Billiontoone (NASDAQ:BLLN) Shares Down 4.6% After Insider Selling 
Guggenheim Maintains Buy on BillionToOne, Raises Price Target to $128 
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
Your note
Sign in to keep a note on BLLN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ATAY OGUZHAN PH.D. | Chief Executive Officer | Sale | Oct 11, 2026 | 0 |
| BREMNER THOMAS S. | Director | Stock Award(Grant) | Jun 9, 2026 | 11,350 |
| HUMMING BIRD VENTURES MANAGEMENT NV | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Nov 6, 2025 | 0 |
| ILERI FIRAT | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 9, 2026 | 40,331 |
| KOLLURI KRISHNA KITTU | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 9, 2026 | 11,350 |
| LYNCH THOMAS P | General Counsel | Conversion of Exercise of derivative security | Oct 12, 2026 | 10,700 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Adams Street Partners, LLC | 4.01% | 1,711,430 | 189.03M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 2.37% | 1,010,322 | 111.59M | Jun 29, 2026 |
| BAILLIE GIFFORD & CO | 2.11% | 901,420 | 99.56M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 1.97% | 840,970 | 92.89M | Jun 29, 2026 |
| Invesco Ltd. | 1.96% | 835,614 | 92.29M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 1.87% | 799,468 | 88.30M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.70% | 724,088 | 79.98M | Jun 29, 2026 |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 1.25% | 531,370 | 58.69M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.23% | 522,864 | 57.75M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.89% | 377,575 | 41.70M | Jun 29, 2026 |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 0.67% | 286,830 | 31.68M | Jun 29, 2026 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Growth Fund | 0.64% | 275,000 | 30.37M | Jun 29, 2026 |